Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to experience a slight decline in performance in 2025, with revenue projected at 5.518 billion yuan (down 0.4% year-on-year) and net profit at 1.915 billion yuan (down 7.1% year-on-year) [3] - Despite the competitive industry landscape, the company is anticipated to maintain strong product capabilities and continue new iterations, leading to a reasonable valuation [3] - The forecast for net profit from 2026 to 2028 is set at 1.956 billion yuan, 2.184 billion yuan, and 2.445 billion yuan respectively, with corresponding EPS of 1.83 yuan, 2.04 yuan, and 2.28 yuan [3] Financial Summary - Revenue for 2025 is reported at 55.18 billion yuan, with a slight decline of 0.4% year-on-year, while net profit is 19.15 billion yuan, reflecting a decrease of 7.1% [3][4] - The gross margin for 2025 is 80.3%, down 1.8 percentage points, influenced by product category structure [4] - The company’s operating income is projected to grow to 6.120 billion yuan in 2026, with a year-on-year increase of 10.9% [6] - The P/E ratio is expected to be 14.8 in 2026, decreasing to 11.8 by 2028, indicating a favorable valuation trend [6] Product and Market Development - The company has received regulatory approval for two types of recombinant collagen medical devices, marking its entry into the skin rejuvenation market and demonstrating its R&D capabilities [5] - The product line includes the upgraded Collagen Stick 2.0 and the newly launched Collagen Big Mask King 3.0, which have received positive market feedback [5] - The company is expanding its market presence internationally, with products now available in Singapore, Malaysia, South Korea, and North America [5]
巨子生物：港股公司信息更新报告：2025年业绩小幅下滑，看好大单品迭代与医美新空间-20260322